Journal
CANCER IMMUNOLOGY IMMUNOTHERAPY
Volume 71, Issue 8, Pages 2041-2049Publisher
SPRINGER
DOI: 10.1007/s00262-021-03122-z
Keywords
Melanoma; Hemagglutinating virus of Japan-envelope; Sendai virus; Innate and adaptive immunotherapy; Clinical trial
Categories
Funding
- Project of Translational and Clinical Research Core Centers (Translational Research Network Program) from Japan Agency for Medical Research and Development, AMED
- project of translational and clinical research core centers
Ask authors/readers for more resources
This study conducted a phase Ia clinical trial of intratumoral administration of GEN0101 in six patients with malignant melanoma. The results showed that GEN0101 had good safety and tolerability, and significant antitumor effects, suggesting its potential as a promising new drug for advanced melanoma patients.
Despite recent advance in immunotherapy agents, safe new therapies that enhance the effects of immune checkpoint inhibitors are still required to develop. We previously demonstrated that hemagglutinating virus of Japan-envelope (HVJ-E) induced not only direct tumor cell death but also antitumor immunity through the activation of T and natural killer (NK) cells, thereafter, developed a manufacturing process of HVJ-E (GEN0101) for clinical use. We here performed a phase Ia clinical trial of intratumoral GEN0101 administration in six patients with stage IIIC or IV malignant melanoma. The primary aim was to evaluate the safety and tolerability of GEN0101, and the secondary aim was to examine the objective tumor response. Patients were separated into two groups (n = 3 each) and received a low dose of 30,000 and high dose of 60,000 mNAU of GEN0101. All patients completed a two-week follow-up evaluation without severe adverse events. The overall response rate was 33% (2 of 6), with 2 partial responses in the high-dose group and 2 with stable disease, and 2 with progressive disease in the low-dose group. Local complete or partial responses were observed in 11 of 18 (61%) target lesions. One patient demonstrated shrinkage of lung metastases after the treatment. The activity of NK cells and interferon-gamma levels were increased in the circulation, indicating augmentation of antitumor immunity by GEN0101. This trial showed not only the safety and tolerability but also the significant antitumor effect of GEN0101, suggesting that GEN0101 might be a promising new drug for patients with advanced melanoma.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available